Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable? Επικοινωνία Submitted by Δημήτρης Σπάχος on Παρ, 12/04/2020 - 16:23
